Balaxi Pharmaceuticals Q2 FY27 Results and WHO-GMP Certification Milestone
Balaxi Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 7:31 pm
Balaxi Pharmaceuticals Q2 FY27 Results and WHO-GMP Certification Milestone Balaxi Pharmaceuticals reported consolidated revenue from operations of ₹8,137.23 lakhs for the quarter ended 30th Sep'26, up 44.85% YoY from ₹5,617.53 lakhs, with net profit surging to ₹115.02 lakhs from ₹20.90 lakhs in the prior-year period. Operationally, the company secured WHO-GMP certification from CDSCO for its Jadcherla formulation facility, scaling commercial production for Angola and Dominican Republic markets with 22 manufactured products and total approvals reaching 34. Additionally, Pranav Maheshwari was re-designated as President – Business and Corporate Strategy, effective 12th Nov'26.
Original exchange filing (PDF)
More announcements from Balaxi Pharmaceuticals Ltd
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation · 16 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding a press release dated November 12, 2026, titled "Balaxi Pharmaceuticals Limited Reports Strong Q2 FY27 Performance; Revenue Grows 45%, EBITDA Surges 338% and PAT Rises 450% YoY". · 13 Nov 2026
- Balaxi Pharmaceuticals Limited has informed the Exchange regarding Progress of the Company's Pharmaceutical Formulation Plant at Jadcherla, Hyderabad. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about change in Management · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding ''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended October 2026". · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 12 Nov 2026
- To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters. · 12 Nov 2026
